|
Week of study
|
p valuea
|
---|
|
0
|
4
|
8
|
12
| |
---|
Total strengthb (kg)
|
Placebo
|
426.7 ± 14.5
|
444.6 ± 14.5
|
457.8 ± 14.5
|
452.0 ± 14.5
| |
HMB-FA
|
426.7 ± 14.5
|
458.7 ± 14.5
|
477.6 ± 14.5
|
503.8 ± 14.5
|
0.0001
|
Squat (kg)
|
Placebo
|
143.8 ± 5.2
|
150.4 ± 5.2
|
155.4 ± 5.2
|
151.1 ± 5.2
| |
HMB-FA
|
143.7 ± 5.2
|
154.9 ± 5.2
|
162.4 ± 5.2#
|
179.9 ± 5.2#
|
0.0001
|
Bench press (kg)
|
Placebo
|
112.9 ± 6.6
|
116.4 ± 6.6
|
118.5 ± 6.6
|
116.7 ± 6.6
| |
HMB-FA
|
112.4 ± 6.6
|
120.8 ± 6.6
|
123.7 ± 6.6
|
125.2 ± 6.6#
|
0.02
|
Deadlift (kg)
|
Placebo
|
170.4 ± 9.2
|
178.2 ± 9.2
|
184.3 ± 9.2
|
184.5 ± 9.2
| |
HMB-FA
|
170.3 ± 9.2
|
182.7 ± 9.2
|
191.2 ± 9.2
|
198.4 ± 9.2#
|
0.009
|
Wingate peak power (W)
|
Placebo
|
879.1 ± 38.3
|
927.0 ± 38.3
|
987.2 ± 38.3
|
982.5 ± 38.3
| |
HMB-FA
|
879.7 ± 38.3
|
936.0 ± 38.3
|
980.7 ± 38.3
|
1,038.6 ± 38.3#
|
0.01
|
Vertical jump power (W)
|
Placebo
|
5,224 ± 73
|
5,636 ± 73
|
5,839 ± 73
|
5,854 ± 73
| |
HMB-FA
|
5,219 ± 73
|
5,835 ± 73#
|
6,039 ± 73#
|
6,211 ± 73#
|
0.001
|
- Adjusted least square mean ± SD for n = 11 HMB (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented participants
-
aProbability of treatment by time difference between the placebo and the HMB-FA treatments over the 12-week study. The mixed model ANOVA in SAS® was used with the main effects of treatment, time and treatment by time, with the value for week 0 used as a covariate
-
bTotal strength as the sum of the 1-RM in bench press, squat, and deadlift
-
#Significantly different than corresponding placebo, t test (p < 0.05)